266 related articles for article (PubMed ID: 15890591)
1. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
3. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
4. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
[TBL] [Abstract][Full Text] [Related]
5. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
[TBL] [Abstract][Full Text] [Related]
6. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
[TBL] [Abstract][Full Text] [Related]
7. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
[TBL] [Abstract][Full Text] [Related]
8. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
9. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
10. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
11. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
[TBL] [Abstract][Full Text] [Related]
15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
16. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
[TBL] [Abstract][Full Text] [Related]
19. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
[TBL] [Abstract][Full Text] [Related]
20. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
Goldner G; Tomicek B; Becker G; Geinitz H; Wachter S; Zimmermann F; Wachter-Gerstner N; Reibenwein J; Glocker S; Bamberg M; Feldmann H; Pötzi R; Molls M; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):78-83. PubMed ID: 17189064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]